New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
13:04 EDTAZN, TEVA, MYLCourt backs AstraZeneca, blocks generic Crestor, Bloomberg reports
A U.S. appeals court ruled in favor of AstraZeneca (AZN), saying its patent on Crestor is valid and enforceable and rejecting challenges made by generic-drug makers including Mylan (MYL) and Teva Pharmaceuticals (TEVA), reported Bloomberg. The ruling protects the valuable cholesterol medicine, which brought in $2.3B in revenue in the first nine months of this year in the U.S., the report noted. Reference Link
News For AZN;MYL;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
September 25, 2015
13:51 EDTMYLBMO's pharma predictions for rest of year include take on Mylan, Perrigo
BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.
09:02 EDTTEVATeva acquires Gecko Health Innovations, terms not disclosed
Subscribe for More Information
08:37 EDTTEVAAntares Pharma could benefit from drug pricing controversy, says Oppenheimer
Subscribe for More Information
07:22 EDTAZN, TEVAEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 24, 2015
15:24 EDTMYLMylan says Perrigo lawsuit 'without merit'
Mylan (MYL) believes that the Perrigo (PRGO) suit filed in Israel is entirely without merit and that Mylan's offer in Israel is valid and proper in all respects. With that said, Perrigo's efforts are entirely futile, as all Perrigo shareholders-institutional and retail, including those in Israel-have always been free to switch their holdings at any time from the Tel Aviv Stock Exchange to the New York Stock Exchange, through a simple, fully automated, well-established system by notifying their broker. As a result, shareholders can participate fully in Mylan's compelling offer without regard to any lawsuits in Israel or any other frustrating actions pursued by Perrigo in Israel. Further, as Mylan has previously stated publicly, it has been its intent and desire to list Mylan's shares on the TASE to maintain liquidity in Israel for the convenience of those shareholders in Israel who prefer to trade on the TASE, and Mylan is already well-advanced in the process of submitting its application to the TASE and the Israel Securities Authority, and is committed to continuing to work closely with these parties to complete this process.
14:17 EDTMYLAppeals court affirms Shire Vyvanse patents valid until 2023
Subscribe for More Information
07:26 EDTTEVATeva stock performance can improve into year-end, says Deutsche Bank
Subscribe for More Information
07:12 EDTTEVATeva added to short-term buy list at Deutsche Bank
Subscribe for More Information
September 23, 2015
08:24 EDTMYLWeakness in drug stocks creates buying opportunities, says RBC Capital
After Hillary Clinton unveiled a plan to lower drug prices, RBC Capital does not expect the plan to be passed by Congress. The firm adds that the plan is positive for generic drug makers and could pressure the FDA to more quickly approve generic drug applications. RBC identifies Insys Therapeutics (IINSY), Endo (ENDP), and Sagent Pharma (SGNT) as three stocks it likes that have suffered "disproportionate selloffs over the last two days." The firm identifies Sagent, Emdo and Mylan (MYL) as three companies with high generic exposure that have sold off.
06:16 EDTMYLMylan countersues Perrigo, cites tender offer 'misstatements,' Reuters reports
Subscribe for More Information
September 22, 2015
08:23 EDTTEVAWith Pharma in 'hot seat,' Citi still likes Allergan, Teva
Subscribe for More Information
08:02 EDTAZNAstraZeneca to present 33 abstracts from respiratory disease portfolio at ERS
Subscribe for More Information
07:43 EDTAZN, TEVADrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:17 EDTAZNAstraZeneca eyes crowd sourcing for better cancer drug cocktails, Reuters says
AstraZeneca's decision release preclinical data from over 50 of its medicines is "unprecedented" in scale and will speed up the hunt for tumor-fighting drug combinations, Reuters says. The company is aiming for a crowd sourcing initiative to help mix the future's cancer drug cocktails, the report says. Reference Link
06:35 EDTMYLMylan to cancel 'stichting' takeover defense
Mylan N.V. yesterday confirmed that on September 19, 2015 the Stichting Preferred Shares Mylan, an independent foundation incorporated under the laws of the Netherlands, requested cancellation of the preferred Mylan shares issued to the Foundation on July 23, 2015. The Foundation informed Mylan it was satisfied that influences that might adversely affect the strategy, mission and other interests of Mylan, its business and its stakeholders to be protected by the Foundation as described in the Foundation's articles of association have been sufficiently addressed. Cancellation of the preferred shares requires Mylan shareholder approval. The Mylan Board of Directors will announce the shareholders meeting to approve the cancellation of the preferred shares in due course.
06:20 EDTTEVALeerink reiterates Outperform on Neurocrine after call with neurologists
Leerink analyst Paul Matteis reiterates an Outperform rating on Neurocrine (NBIX) after speaking with two neurologists on the clinical potential of the company's NBI-98854 and Teva's (TEVA) SD-809 for the treatment of Tardive Dyskinesia, Tourette's Syndrome and Huntington's Chorea. Matteis left the call "increasingly optimistic" on the likelihood of NBI-98854 showing Phase III success for Tardive Dyskinesia. The analyst has a $67 price target for shares.
06:19 EDTAZNClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:28 EDTAZNTuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTAZNHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.
05:46 EDTMYLMylan reinstated with an Equal Weight at Barclays
Barclays analyst Douglas Tsao reinstated Mylan (MYL) with an Equal Weight rating and $57 price target. The analyst expects uncertainty around the company's tender offer for Perrigo (PRGO) to weigh on the shares over the near term.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use